Verastem Stops Lung Cancer Trial to Focus on More Promising Treatment
Verastem Oncology discontinues RAMP 203 trial for KRAS G12C lung cancer to prioritize VS-7375, showing 69% response rate in KRAS G12D patients.
NOTRELOAD AI
Greenwich LifeSciences Extends Share Lock-up Through 2026
Greenwich LifeSciences (GLSI) announces 6-year share lock-up extension for directors and officers to support FLAMINGO-01 breast cancer trial through September 2026.
Tesla Cybertruck Battery Supplier Slashes Contract by 99%
South Korean battery supplier L&F cuts Tesla Cybertruck contract from $2.67B to just $7K due to production delays and weak demand for the electric pickup truck.
Genmab Stops Development of Acasunlimab to Focus on Key Cancer Treatments
Genmab discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline.
Enphase Energy Gets a Boost as Analysts See Strong 2026 Outlook
Northland raises Enphase Energy’s price target and names it a Top Pick for 2026, citing new products and a solar market recovery.
D. Boral Starts Coverage on Turn Therapeutics with Buy Rating and $8 Target
D. Boral Capital begins coverage of Turn Therapeutics with a Buy rating, citing strong dermatology focus, upcoming clinical data, and long-term growth potential.